7 News & Press Releases found
Ocean Biomedical News
-
Discovery of a Whole New Class of Antimalarial Drugs Which Target PfGARP and Kill Malaria Parasites
Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the ...
-
Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a ...
-
Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital
NEW YORK and PROVIDENCE, R.I., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther” or the “Company”), a special purpose acquisition company (SPAC) has entered into an Agreement and ...
-
Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ
Ocean Biomedical’s innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. Ocean Biomedical’s ...
-
Journal Publication: CHI3L1 regulates PD-L1 and anti–CHI3L1–PD-1 antibody elicits synergistic antitumor responses.
“Master Pathway” Discovery. Congratulations to our Founder and Scientific Advisory Board Chairman, Dr. Jack A. Elias, on the publication of his breakthrough lung cancer research in the Journal of Clinical Investigation. Referring to ...